Company: NCNA
Filing Date: 2025-06-18
Form Type: F-3/A
Source: 0001193125-25-142565
Chunk: 11

Company: NuCana plc
Filing Date: 2025-06-18
Form: F-3/A
Chunk 11
---
 by reference in this prospectus. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the
cautionary statements contained or referred to in this section.

7

CAPITALIZATION

A prospectus supplement or report on Form 6-K incorporated by reference into the registration
statement of which this prospectus forms a part will include information on our consolidated capitalization.

8

USE OF PROCEEDS

Unless otherwise indicated in the applicable prospectus supplement, we intend to use any net proceeds from the sale of securities under this
prospectus to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions,
should we choose to pursue any, and collaborations. We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net
proceeds, if any, we receive in connection with securities offered pursuant to this prospectus for any purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade and
interest-bearing securities.

9

PLAN OF DISTRIBUTION We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities (1) through underwriters or dealers, (2) through agents or (3) directly to one or more purchasers, or through a combination of such methods. We may distribute the securities from time to time in one or more transactions at:

| • |     | a fixed price or prices, which may be changed from time to time; |

| • |     | market prices prevailing at the time of sale; |

| • |     | prices related to the prevailing market prices; or |

| • |     | negotiated prices. |

We may directly solicit offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase the securities from time to time, and may enter into arrangements for “at-the-market,”equity line or similar transactions. We will name in a prospectus supplement any under